GSK reports 4.08 billion voting rights in August 2025 FCA notice

Rhea-AI Filing Summary

GSK plc has filed a Form 6-K to meet Financial Conduct Authority (FCA) Disclosure Guidance & Transparency Rule 5.6.1R. As of 31 July 2025 the company had 4,315,385,410 issued Ordinary Shares of 31 ¼ pence each. Of these, 237,044,421 shares were held in treasury, leaving 4,078,340,989 voting rights in circulation. Shareholders should use this denominator when calculating threshold notifications of holdings under FCA rules. The notice was authorised by Company Secretary V. A. Whyte and filed on 1 August 2025.

Insights

Financial Analyst

TL;DR: Routine share-count update; 4.08 bn voting rights outstanding, no dilution or buyback signalled—valuation impact neutral.

The filing simply refreshes the market on GSK’s share count and treasury position in line with FCA Rule 5.6.1R. No share issuances, cancellations or buy-back activity are disclosed, so equity value per share and EPS math remain unchanged. Investors may update their models to reflect 4.078 bn voting rights but should not expect financial or strategic implications from this administrative notice.

Corporate Governance Specialist

TL;DR: Governance-driven disclosure; ensures transparency for substantial holding notifications, otherwise immaterial.

Filing maintains compliance with UK transparency rules by publicly stating the precise denominator for ownership threshold calculations. The presence of 237 m treasury shares equates to c.5.5% of issued capital, giving the board flexibility for incentive plans or future buy-backs, yet today’s notice does not commit to any action. Impact on governance assessments is neutral.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2025

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

GSK plc

Total Voting Rights and Capital

In conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R, GSK plc (the 'Company') hereby notifies the market of the following:

The Company's issued share capital as at 31 July 2025 consisted of 4,315,385,410 shares of 31 ¼ pence each ('Ordinary Shares'), of which 237,044,421 Ordinary Shares were held in Treasury.

Therefore, the total number of voting rights in the Company is 4,078,340,989. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

Notifications may be sent to company.secretary@gsk.com.

V A Whyte

Company Secretary

1 August 2025

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GSK plc

(Registrant)

Date: August 01, 2025

By:/s/ VICTORIA WHYTE

--------------------------

Victoria Whyte

Authorised Signatory for and on

behalf of GSK plc

FAQ

How many voting rights does GSK (GSK) report as of 31 July 2025?

GSK states there are 4,078,340,989 voting rights outstanding.

What is GSK plc’s total issued share capital on 31 July 2025?

The company has 4,315,385,410 Ordinary Shares of 31 ¼ pence each in issue.

How many GSK shares are held in treasury?

GSK holds 237,044,421 Ordinary Shares in treasury.

Why is the voting rights figure important for shareholders?

It serves as the denominator when investors calculate whether they must notify the FCA of reaching ownership thresholds.

When was this information filed and in what form?

It was filed on 1 August 2025 via a Form 6-K report.